This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Galcanezumab for the prevention of chronic migraine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Calcitonin gene-related peptide (CGRP) is a promising target for migraine prevention
  • Galcanezumab is a humanized monoclonal antibody that selectively binds to and blocks the physiologic activity of CGRP
  • patients with episodic migraine treated with galcanezumab had a significantly greater mean reduction in the number of monthly migraine headache days (MHDs) and low rates of treatment discontinuation compared with those treated with placebo

Galcanezumab is recommended as an option for preventing migraine in adults, only if:

  • they have 4 or more migraine days a month
  • at least 3 preventive drug treatments have failed and
  • the company provides it according to the commercial arrangement

Stop galcanezumab after 12 weeks of treatment if:

  • in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50%
  • in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.